Bisacodyl (Fenilaxan) is a diphenylmethane stimulant laxative used for the treatment of constipation and for bowel evacuation.

Bisacodyl inhibits the absorption of water in rats' jejunum, ileum, and colon, with the degree of inhibition linearly correlated to the logarithm of bisacodyl concentration. At a dosage of 4.3 mg/kg, bisacodyl, in combination with AOM, increases the number of microcysts per colony in rats without increasing tumor numbers. However, a higher dosage of 43 mg/kg significantly raises both the microcyst and tumor counts. Compared to rats treated with saline, bisacodyl (5.9 mg/kg) significantly reduces the activity of jejunum and colon (Na + K) ATPases. Furthermore, at 5.9 mg/kg, bisacodyl markedly increases PGE2 levels and stimulates adenylate cyclase activity in the jejunum and colon, without affecting cAMP levels. Oral administration of 10 mg/kg bisacodyl significantly decreases NOS activity in the rat jejunum. Meanwhile, 20 mg/kg bisacodyl leads to a reduction in AQP3 protein expression and an increase in TNF-α mRNA expression levels in the rat colon.

At a concentration of 10 μg/mL, Bisacodyl acts on Raw264.7 cells, leading to an increase in the mRNA expression levels of TNF-α, COX2, and PGE2.